Intraoperative Neuromonitoring of Pelvic Autonomous Nerve Plexus During Total Mesorectal Excision

September 3, 2025 updated by: Perivoliotis Konstantinos, Larissa University Hospital
The purpose of this research protocol is the evaluation of the improvement of the anorectal and urogenital urinary function, alongside the postoperative quality of life after the application of pIONM in patients submitted to TME for rectal cancer.

Study Overview

Status

Recruiting

Conditions

Detailed Description

The introduction of Total Mesorectal Excision (TME) resulted to the improvement of the overall survival and local recurrence rates of rectal cancer patients. However, the associated urogenital and anorectal functional deficit has a significant effect on the postoperative quality of life of the patient. More specifically, the postoperative rates of urogenital and sexual dysfunction that have been reported in the various series, are estimated at the levels of 70% and 90%, respectively. Additionally, TME is associated with the development of the low anterior syndrome (LARS). LARS is characterized by the onset of fecal incontinence, due to injury in the autonomic nerve plexuses that innervate the internal anal sphincter (IAS); who in turn is responsible for the 52-85% anal resting tone. According to a recent study, 38.8% and 33.7% of patients with normal preoperative urogenital function, developed postoperative stool and urine incontinence, respectively.

It becomes apparent that the incidence rates of these complications vary between the various series, mainly due to their small sample size, the lack of comparative data, the short follow up period, the use of non-validated tools and their retrospective design. Several predictive factors of these adverse events have been suggested in the literature, including old age, tumors located less than 12 cm from the anal verge, preoperative radiotherapy and injury to the pelvic autonomous nerves.

The clinical and functional anatomy of the pelvis are quite complex. The inferior hypogastric plexus is formed by the parasympathetic pelvic nerves, deriving from the I2-I4 and the sympathetic hypogastric nerve. It is a neural anatomic structure that carries organ-specific nerve fibers. Visual identification of the plexus is quite difficult, for various reasons, including the complexity of the nerve distribution, the narrow pelvis, the voluminous mesorectum, obesity, previous pelvic operations, neoadjuvant radiotherapy, locally advanced tumors, intraoperative bleeding and the extensive use of diathermy. According to the current literature, identification of the autonomous pelvic plexus is achievable in 72% of cases, whereas partial localization is possible only in 10.7% of patients.

Theoretically, intraoperative neuromonitoring of the pelvic autonomous nerves (pIONM), could quantify intraoperative nerve injuries, while in parallel, contribute to the improvement of the patients' postoperative quality of life. Several pIONM techniques have been described, including intra-urethral and intra-vesical pressure measurements. However, it was found that intermittent neuromonitoring objectifies the macroscopic integrity assessment of the sacral plexus. Recently, a promising technique, based on the simultaneous electromyography of the IAS and bladder manometry was developed, with encouraging results. During pIONM, the surgeon delivers electric stimuli to the autonomic nerve structures through a hand-held stimulator. At the same time, electromyogram changes of the IAS and the external anal sphincter (EAS), alongside intravesical pressure gradients are assessed.

Intraoperative neuromonitoring has been evaluated in several experimental studies. In a recent study, intraoperative simulation of the inferior hypogastric plexus with a bipolar stimulator resulted to the appearance of a measurable and repeatable electromyographic signal from the IAS.

Simultaneous signal processing from the IAS and urinary bladder, improves the, overall, diagnostic accuracy of these techniques. Stabilization of the electrodes outside the surgical field, has been, also, suggested by some researchers. Additionally, experimental studies evaluated the role of pIONM in the minimal invasive TME.

Moreover, the effectiveness of this technique has been a research subject in multiple clinical trials. In another study, where 85 patients underwent TME, after logistic regression, no use of pIONM and neoadjuvant radiotherapy, were identified as independent prognostic factors of postoperative urogenital deficit. Furthermore, the use of pIONM, was associated with a 100% sensitivity and a 96% specificity for the postoperative development of urogenital and anorectal functional complications.

The application of pIONM has been also suggested in the laparoscopic and robotic TME, using specially designed stimulators. In another trial, preservation of the plexus was achieved in 51.7% of patients submitted to a laparoscopic low anterior resection for rectal cancer. During one year follow-up, patients receiving pIONM, displayed a superiority in terms of postoperative urogenital function, as assessed by the IIEF, IPSS and FSFI questionnaires.

Study Type

Interventional

Enrollment (Estimated)

44

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

  • Name: Konstantinos Perivoliotis, MD
  • Phone Number: 00302413501000
  • Email: kperi19@gmail.com

Study Locations

      • Larissa, Greece, 41110
        • Recruiting
        • University Hospital Of Larissa
        • Contact:
        • Sub-Investigator:
          • Anastasios Manolakis, PhD
        • Sub-Investigator:
          • Michael Samarinas, PhD
        • Sub-Investigator:
          • Aikaterini Tsiogga, MSc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

14 years to 86 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Description

Inclusion Criteria:

  • Histologically confirmed rectal cancer
  • Surgical resection with TME
  • <90 years old
  • Signed informed consent

Exclusion Criteria:

  • Emergency operation
  • Presence of pacemaker
  • Partial mesorectal excision
  • Sepsis or systematic infection
  • Physical or mental impairment
  • Pregnancy or nursing
  • Insufficient preoperative data for the urogenital/ anorectal function
  • Lack of compliance with the research process

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: pIONM

In the experimental group pIONM will be performed intraoperatively. For the implementation of pIONM, a special device, that allows simultaneous monitoring of sphincter signals and bladder manometry, will be introduced. This device will employ the placement of a bipolar electrode in the internal and external anal sphincter. Moreover, another electrode will be placed on the surrounding tissues. For bladder manometry, the catheter will be connected to the pressure sensor, and subsequently to the pIONM monitor. Intraoperatively, depending on the approach (open or laparoscopic), the respective bipolar stimulator will be used.

Prior to the initiation of pIONM, urinary bladder will be drained and filled with 200 ml R/L. The pIONM parameters will be the following: 1-25 milliampere current, 30 Hz frequency and 200 μs monophasic pulses.

Pelvic Intraoperative Neuromonitoring (pIONM) allows mapping of the pelvic autonomous plexus during total mesorectal excision (TME).
No Intervention: Control
In the control group pIONM will not be performed intraoperatively

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Change in the quality of life of the patient at 3 months postoperatively, based on the SF-36 questionnaire
Time Frame: Preoperatively, 3 months postoperatively
Change in the quality of life of the patient, at 3 months postoperatively, compared to the respective preoperative measurements, based on the Short Form 36 (SF-36) questionnaire SF-36: Short Form Survey Minimum Value: 0 Maximum Value: 100 Higher scores indicate a better outcome
Preoperatively, 3 months postoperatively

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Operative time
Time Frame: Intraoperative period
The total operative time will be recorded. Measurement unit: minutes
Intraoperative period
Intraoperative bleeding
Time Frame: Intraoperative period
The total intraoperative blood loss volume will be recorded. Measurement unit: mL
Intraoperative period
Postoperative discharge time
Time Frame: Maximum time frame 15 days postoperatively
Postoperative time that the patient can be safely discharged. Measurement unit: hours. The patient will be discharged, when it is ensured that is medically safe to be released. In particular, as the exit time of the patient, will be regarded the time that the patient will fulfil the Clinical Discharge Criteria. More specifically, the patient should meet the following : steady vital signs, be oriented, without nausea or vomiting, mobilized with a steady gait, without a significant bleeding
Maximum time frame 15 days postoperatively
Postoperative complications
Time Frame: 1 month postoperatively
Occurrence of postoperative complications (based on Clavien-Dindo classification). If such an episode occurs, then it will be defined as=1 'YES' If such an episode does not occur, then it will be defined as=0 'NO'
1 month postoperatively
Negative resection margin
Time Frame: 1 month postoperatively
Occurrence of negative resection margin. If such an episode occurs, then it will be defined as=1 'YES' If such an episode does not occur, then it will be defined as=0 'NO'
1 month postoperatively
Local recurrence
Time Frame: 1 year postoperatively
Occurrence of local recurrence. If such an episode occurs, then it will be defined as=1 'YES' If such an episode does not occur, then it will be defined as=0 'NO'
1 year postoperatively
Bladder capacity
Time Frame: Preoperatively and 2 months postoperatively
Urodynamic assessment. Evaluation of bladder capacity. Measurement unit: ml
Preoperatively and 2 months postoperatively
Bladder compliance
Time Frame: Preoperatively and 2 months postoperatively
Urodynamic assessment. Evaluation of bladder compliance. Measurement unit: ml/cm H2O
Preoperatively and 2 months postoperatively
Detrusor pressure at maximum flow
Time Frame: Preoperatively and 2 months postoperatively
Urodynamic assessment. Evaluation of detrusor pressure at maximum flow. Measurement unit: cm H2O
Preoperatively and 2 months postoperatively
Maximum urinary flow rate
Time Frame: Preoperatively and 2 months postoperatively
Urodynamic assessment. Evaluation of maximum urinary flow rate. Measurement unit: ml/s
Preoperatively and 2 months postoperatively
Voiding volume
Time Frame: Preoperatively and 2 months postoperatively
Urodynamic assessment. Evaluation of voiding volume. Measurement unit: ml
Preoperatively and 2 months postoperatively
Post-void residual
Time Frame: Preoperatively and 2 months postoperatively
Urodynamic assessment. Evaluation of post-void residual. Measurement unit: ml
Preoperatively and 2 months postoperatively
Anal canal resting phase pressure
Time Frame: Preoperatively and 2 months postoperatively
High-resolution Anorectal Manometry assessment. Evaluation of anal canal resting phase pressure. Measurement unit: mmHg
Preoperatively and 2 months postoperatively
Sphincter zone length
Time Frame: Preoperatively and 2 months postoperatively
High-resolution Anorectal Manometry assessment. Evaluation of sphincter zone length. Measurement unit: cm
Preoperatively and 2 months postoperatively
Short squeeze test
Time Frame: Preoperatively and 2 months postoperatively
High-resolution Anorectal Manometry assessment. Evaluation of short squeeze (5sec) pressure. Measurement unit: mmHg
Preoperatively and 2 months postoperatively
Long squeeze test
Time Frame: Preoperatively and 2 months postoperatively
High-resolution Anorectal Manometry assessment. Evaluation of long squeeze (30sec) pressure. Measurement unit: mmHg
Preoperatively and 2 months postoperatively
Cough test
Time Frame: Preoperatively and 2 months postoperatively
High-resolution Anorectal Manometry assessment. Evaluation of cough test (0 and 50 ml). If such an episode occurs, then it will be defined as=1 'YES' If such an episode does not occur, then it will be defined as=0 'NO'
Preoperatively and 2 months postoperatively
Push test
Time Frame: Preoperatively and 2 months postoperatively
High-resolution Anorectal Manometry assessment. Evaluation of push test (0 and 50 ml). If such an episode occurs, then it will be defined as=1 'YES' If such an episode does not occur, then it will be defined as=0 'NO'
Preoperatively and 2 months postoperatively
RAIR test
Time Frame: Preoperatively and 2 months postoperatively
High-resolution Anorectal Manometry assessment. Evaluation of rectoanal inhibitory reflex (RAIR) test (20 and 50 ml). If such an episode occurs, then it will be defined as=1 'YES' If such an episode does not occur, then it will be defined as=0 'NO'
Preoperatively and 2 months postoperatively
Difference in the quality of life of the patient, based on the SF-36 questionnaire
Time Frame: Preoperatively, 6, 12, 24 months postoperatively
Difference in the quality of life of the patient, at 6, 12, 24 months postoperatively, compared to the respective preoperative measurements, based on the Short Form 36 (SF-36) questionnaire SF-36: Short Form Survey Minimum Value: 0 Maximum Value: 100 Higher scores indicate a better outcome
Preoperatively, 6, 12, 24 months postoperatively
Difference in the erectile function of the patient, based on the IIEF questionnaire
Time Frame: Preoperatively, 3, 6, 12, 24 months postoperatively
Difference in the erectile function of the patient, at 3, 6, 12, 24 months postoperatively, compared to the respective preoperative measurements, based on the International Index of Erectile Function (IIEF) questionnaire IIEF: International Index of Erectile Function Minimum Value: 0 Maximum Value: 5 Higher scores indicate a better outcome
Preoperatively, 3, 6, 12, 24 months postoperatively
Difference in the sexual function of the patient, based on the FSFI questionnaire
Time Frame: Preoperatively, 3, 6, 12, 24 months postoperatively
Difference in the sexual function of the patient, at 3, 6, 12, 24 months postoperatively, compared to the respective preoperative measurements, based on the Female Sexual Function Index (FSFI) questionnaire FSFI: Female Sexual Function Index Minimum Value: 2 Maximum Value: 36 Higher scores indicate a better outcome
Preoperatively, 3, 6, 12, 24 months postoperatively
Difference in the prostate symptoms of the patient, based on the IPSS questionnaire
Time Frame: Preoperatively, 3, 6, 12, 24 months postoperatively
Difference in the prostate symptoms of the patient, at 3, 6, 12, 24 months postoperatively, compared to the respective preoperative measurements, based on the International Prostate Symptom Score (IPSS) questionnaire IPSS: International Prostate Symptom Score Minimum Value: 0 Maximum Value: 35 Higher scores indicate a worse outcome
Preoperatively, 3, 6, 12, 24 months postoperatively
Difference in the low anterior syndrome symptoms of the patient, based on the LARS questionnaire
Time Frame: Preoperatively, 3, 6, 12, 24 months postoperatively
Difference in the low anterior syndrome symptoms of the patient, at 3, 6, 12, 24 months postoperatively, compared to the respective preoperative measurements, based on the Low Anterior Resection Syndrome (LARS) questionnaire LARS: Low Anterior Resection Syndrome Minimum Value: 0 Maximum Value: 42 Higher scores indicate a worse outcome
Preoperatively, 3, 6, 12, 24 months postoperatively

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Director: Konstantinos Tepetes, Prof, Department of Surgery, University Hospital of Larissa
  • Principal Investigator: Konstantinos Perivoliotis, MD, Department of Surgery, University Hospital of Larissa

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

September 19, 2021

Primary Completion (Estimated)

September 19, 2027

Study Completion (Estimated)

September 19, 2028

Study Registration Dates

First Submitted

June 22, 2021

First Submitted That Met QC Criteria

June 30, 2021

First Posted (Actual)

July 2, 2021

Study Record Updates

Last Update Posted (Estimated)

September 4, 2025

Last Update Submitted That Met QC Criteria

September 3, 2025

Last Verified

September 1, 2025

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

IPD Plan Description

No plan to share individual patient data

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Rectal Neoplasms

Clinical Trials on Pelvic Intraoperative Neuromonitoring

Subscribe